Apologies if this was already posted, the FDA gave a stem cell therapeutic candidate a rare pediatric drug designation (RPDD) to treat cardiomyopathy associated with rare and fatal Danon disease. Another stem cell based therapeutic candidate able to generate new cardiac tissue to create a functional human heart muscle to add to the list. The tide has is most definitely turning in MSB's favour:
https://www.pharmacytimes.com/view/fda-awards-rare-pediatric-drug-designation-to-stem-cell-product-candidate-for-fatal-danon-disease
Cell Therapy News/Articles, page-16345
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |